Clinical Trial

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Protocol Amendment History 3 changes
notable Enrollment reduced: 100 -> 79 participants 2026-08-01
notable Primary completion pushed: 2026-06 -> 2027-12 2026-08-01
minor Completion pushed: 2026-12 -> 2027-12 2026-08-01
Trial Details
NCT Number NCT06347159
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Hypertrophic Cardiomyopathy
Enrollment 79 participants
Start Date 2024-04-11
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31